Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from REGN

Regeneron Posts Drop In Q1 Profit As COVID Antibody Sales Hit, Shares Fall

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $11.49 per share for Q1 FY22, up 16% Y/Y, beating the $10.04 estimate. Sales increased 17% to $2.96 billion, surpassing the analysts' consensus of $2.73 billion, fueled by sales of COVID-19 treatment, REGEN-COV. The company reported a net income of $974 million, down 13%, as its COVID-19…

Benzinga

Why The First Quarter Could Be A 'High-Water Mark' For Regeneron

The first quarter could represent a "high-water mark" for Regeneron Pharmaceuticals, an analyst said Wednesday.

Investors Business Daily

Regeneron Pharmaceuticals: Q1 Earnings Insights

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Dow Jones Futures: New Market Rally Awaits Fed Decision; AMD, Lithium Play Livent Jump Late

The major indexes rose slightly Tuesday, but stocks in these groups made bullish moves.

Investors Business Daily

Earnings Preview: Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Regeneron Pharmaceuticals will report an earnings per share (EPS) of $10.04.

Benzinga

Where Regeneron Pharmaceuticals Stands With Analysts

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

Benzinga

Here's Why This Analyst Cut Price Target On Regeneron

RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment. The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

If You Invested $100 In Regeneron Pharmaceuticals 10 Years Ago, Here's How Much You Would Have Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.58% on an annualized basis producing an average annual return of 18.92%. Currently, Regeneron Pharmaceuticals has a market capitalization of $78.02 billion.

Benzinga

5 Outperforming Biotech Stocks with More Room to Run

Thanks to the global COVID-19 vaccination drive and inelastic demand for healthcare, biotechnology stocks have been outperforming the broader markets so far this year. Because this trend will likely continue, we think investing in popular biotech stocks Regeneron Pharmaceuticals (REGN), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Incyte Corp.…

StockNews.com

FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy

The FDA has extended its review of Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) marketing application of REGEN-COV (casirivimab and imdevimab) for non-hospitalized COVID-19 patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure prophylactic use. Regeneron has submitted additional data from its completed prophylaxis trial that the…

Benzinga

Analyst Ratings for Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter:

Benzinga

This Is What Whales Are Betting On Regeneron Pharmaceuticals

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 11 strange trades.

Benzinga

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 11.29% on an annualized basis producing an average annual return of 18.54%. Currently, Regeneron Pharmaceuticals has a market capitalization of $77.02 billion.

Benzinga

Regeneron Builds On Retinal Disease Expertise Via Gene Therapy Pact With ViGeneron

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) beefed up its gene therapy capabilities after signing a new deal with the German biotech ViGeneron. The companies did not specify their target but noted it would be some inherited retinal disease. It's an area where Regeneron has much expertise. One of its best-selling products, Eylea, is approved to treat…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Rise, Oil Prices Tumble; Tesla Jumps On Stock Split Plan

The market rally has been strong despite surging bond yields, but for now. Tesla popped on plans for a stock split.

StockNews.com

Buy the Dip in 3 Top-Rated Large-Cap Stocks

The increasing economic sanctions on Russia and consequent surge in oil prices and supply-chain disruptions will surely keep the stock market under pressure. Therefore, we think it could be wise to buy the price dip in quality large-cap stocks Regeneron Pharmaceuticals (REGN), Telefonaktiebolaget LM Ericsson (ERIC), and PPG Industries (PPG)…

Benzinga

BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC

BioNTech SE (NASDAQ:BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with advanced NSCLC and share…

Benzinga

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Erase Losses On Russia Comments; Market Rally At Key Level

Futures rose with Russia/Ukraine tensions in focus after the stock market rally sold off Friday. Tesla China sales were strong.

Investors Business Daily

Regeneron Scores Quarterly Beat — But How Long Will Its Covid Tailwind Persist?

Regeneron snagged a quarterly beat Friday, reporting sales growth almost entirely attributed to its Covid cocktail — and REGN stock rose.

Benzinga

Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned

Benzinga

Recap: Regeneron Pharmaceuticals Q4 Earnings

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Preview For Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Regeneron Pharmaceuticals will likely report an Earnings Per Share (EPS) of $18.11.

Benzinga

Analyst Ratings For Regeneron Pharmaceuticals

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

Benzinga

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.